Amplia Therapeutics Limited, a clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. Its product pipeline comprises Narmafotinib (AMP945), an inhibitor of FAK, which is in phase 2b clinical trial for pancre... Amplia Therapeutics Limited, a clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. Its product pipeline comprises Narmafotinib (AMP945), an inhibitor of FAK, which is in phase 2b clinical trial for pancreatic cancer; and treatment of ovarian cancer. It also develops AMP886 for application in oncology and chronic fibrosis indications. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia. 詳細を表示
| 期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.02 | 17.3913043478 | 0.115 | 0.15 | 0.115 | 2266357 | 0.12183364 | DE |
| 4 | -0.005 | -3.57142857143 | 0.14 | 0.15 | 0.105 | 1476965 | 0.12093464 | DE |
| 12 | -0.125 | -48.0769230769 | 0.26 | 0.26 | 0.105 | 2314890 | 0.15385559 | DE |
| 26 | 0.01 | 8 | 0.125 | 0.275 | 0.1 | 2713272 | 0.19205387 | DE |
| 52 | -0.035 | -20.5882352941 | 0.17 | 0.425 | 0.1 | 2833294 | 0.20856296 | DE |
| 156 | 0.046 | 51.6853932584 | 0.089 | 0.425 | 0.049 | 1646347 | 0.17451528 | DE |
| 260 | -0.09 | -40 | 0.225 | 0.425 | 0.049 | 1055594 | 0.17303015 | DE |
ExtremelyBullishZig
4分前
meirluc
5分前
watcher777
7分前
MrBobbob
7分前
Ronnie Replay
9分前
Southern Gal
10分前
High_Desert
16分前
DJurg
22分前
mascale
35分前
JamesF1
35分前
ysung
37分前
Guido2
38分前
wshaw14
39分前
LegendaryOracle941
41分前
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約
すでにアカウントをお持ちですか? サインイン
アカウントをお持ちでないですか? 登録
登録することで、ADVFN の 利用規約 を読み、理解し、同意したこと、および私が個人投資家であることを確認します。